Related Experiment Videos
Endometrial ablation with NovaSure GEA, a pilot study
Bjorn Busund1, Lars Espen Erno, Anne Grønmark
1Department of Gynecology, Ullevaal University Hospital, 0407 Oslo, Norway. oistre@c2i.net
Acta Obstetricia Et Gynecologica Scandinavica
|February 13, 2003
Summary
The NovaSure Global Endometrial Ablation (GEA) system effectively treated severe menorrhagia in women with dysfunctional uterine bleeding (DUB), achieving amenorrhea in 58% of patients after 12 months.
Area of Science:
- Gynecology
- Minimally Invasive Surgery
- Reproductive Medicine
Background:
- Dysfunctional uterine bleeding (DUB) causes severe menorrhagia, impacting quality of life.
- Medical therapies for DUB are often ineffective for severe cases.
- Endometrial ablation offers a surgical alternative for menorrhagia management.
Purpose of the Study:
- To assess the safety and efficacy of the NovaSure Global Endometrial Ablation (GEA) system.
- To evaluate NovaSure GEA in premenopausal women with severe menorrhagia due to DUB.
- To determine amenorrhea rates and complications following NovaSure GEA.
Main Methods:
- Prospective, single-arm, multicenter, observational pilot study.
- 46 premenopausal women with DUB-related menorrhagia unresponsive to medical therapy were enrolled.
- NovaSure GEA was performed under sedation with para-cervical block; bleeding scores were tracked for 12 months.
Main Results:
- No serious intraoperative complications were reported.
- Treatment duration averaged 94 seconds.
- At 12 months, 58% of patients achieved amenorrhea (complete cessation of uterine bleeding).
Conclusions:
- The NovaSure GEA system demonstrated preliminary effectiveness in treating severe menorrhagia secondary to DUB.
- Achieving 58% amenorrhea at 12 months suggests NovaSure GEA is a viable treatment option.
- Further research may confirm NovaSure GEA's long-term safety and efficacy profile.